Rachel King

Rachel King has extensive experience in the biotechnology and healthcare sectors, serving as a board member for multiple organizations, including the University of Maryland BioPark and GlycoMimetics. Since 2005, King has held significant positions at the Biotechnology Innovation Organization, including Chief Executive Officer and Chair of the Board of Directors. Prior to their current roles, King was CEO of Genetic Therapy, Inc., and held senior leadership positions at Novartis and New Enterprise Associates. King holds an AB from Dartmouth College and an MBA from Harvard Business School, and is currently a candidate for a Master's in Writing Fiction at Johns Hopkins University.